drugset / Trial / NCT01198613
ToleroMune Ragweed Exposure Chamber Study
Phase 2
Completed
275 enrolled
Circassia Limited
Adiga Life Sciences, Inc. · collabCetero Research, San Antonio · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
It is believe that ragweed is the primary cause of autumn allergies and 87% of patients with ragweed allergy suffer rhinoconjunctivitis. ToleroMune Ragweed is a novel, synthetic, allergen-derived peptide desensitising vaccine, currently being developed for the treatment of ragweed allergy. This study will look at the efficacy, safety and tolerability of two doses of ToleroMune Ragweed in ragweed allergic subjects following challenge with ragweed in an EEC.
Timeline
- Start
- 2010-09
- Primary completion
- 2011-08
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ToleroMune Ragweed | Vaccine | — | Other |